115 related articles for article (PubMed ID: 35505251)
1. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
Salminen JK; Mehtola A; Talala K; Taari K; Mäkinen J; Peltola J; Tammela TLJ; Auvinen A; Murtola TJ
Br J Cancer; 2022 Sep; 127(4):704-711. PubMed ID: 35505251
[TBL] [Abstract][Full Text] [Related]
2. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Salminen JK; Kuoppamäki V; Talala K; Taari K; Mäkinen J; Peltola J; Tammela TLJ; Auvinen A; Murtola TJ
Int J Cancer; 2021 Jul; 149(2):307-315. PubMed ID: 33634851
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of prostate cancer screening among men using antidiabetic medication.
Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
[TBL] [Abstract][Full Text] [Related]
8. Allopurinol and prostate cancer survival in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):73-80. PubMed ID: 36131010
[TBL] [Abstract][Full Text] [Related]
9. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Kinnunen PT; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2016 Dec; 50(6):413-419. PubMed ID: 27628763
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
Joentausta RM; Rannikko A; Murtola TJ
Prostate; 2019 May; 79(6):583-591. PubMed ID: 30652328
[TBL] [Abstract][Full Text] [Related]
11. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
12. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Peltomaa AI; Talala K; Määttänen L; Taari K; Tammela TLJ; Auvinen A
Eur Urol Focus; 2017 Apr; 3(2-3):212-220. PubMed ID: 28753762
[TBL] [Abstract][Full Text] [Related]
13. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
[TBL] [Abstract][Full Text] [Related]
14. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial.
Veitonmäki T; Murtola TJ; Määttänen L; Taari K; Stenman UH; Tammela TL; Auvinen A
Prostate; 2015 Sep; 75(13):1394-402. PubMed ID: 26073992
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
Kinnunen PTT; Murtola TJ; Talala K; Taari K; Tammela TLJ; Auvinen A
BMC Cancer; 2017 Aug; 17(1):585. PubMed ID: 28851310
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
Kaapu KJ; Murtola TJ; Määttänen L; Talala K; Taari K; Tammela TL; Auvinen A
Cancer Causes Control; 2016 Feb; 27(2):157-64. PubMed ID: 26573846
[TBL] [Abstract][Full Text] [Related]
17. Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden.
George G; Garmo H; Adolfsson J; Elf K; Gedeborg R; Holmberg L; Stattin P; Styrke J; Van Hemelrijck M
J Oncol; 2023; 2023():9527920. PubMed ID: 36844872
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial.
Murtola TJ; Tammela TL; Määttänen L; Huhtala H; Platz EA; Ala-Opas M; Stenman UH; Auvinen A
Int J Cancer; 2010 Oct; 127(7):1650-9. PubMed ID: 20073066
[TBL] [Abstract][Full Text] [Related]
19. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
